This vaccine platform was reported to become well tolerated and immunogenic within a Phase 1/2a trial of 120 participants6
This vaccine platform was reported to become well tolerated and immunogenic within a Phase 1/2a trial of 120 participants6. an improved knowledge of its systems… Read More »This vaccine platform was reported to become well tolerated and immunogenic within a Phase 1/2a trial of 120 participants6